IPO前夕股东折价“出逃”!百济神州“断供”后,维立志博“零收入”冲港|创新药观察

华夏时报
18 Jun

华夏时报(www.chinatimes.net.cn)记者 于娜 见习记者 赵文娟 北京报道南京维立志博生物科技股份有限公司(下称“维立志博”)再度向港交所递交招股书,谋求主板上市,摩根士丹利与中信证券担任联席保荐人。作为一家深耕肿瘤、自身免疫性疾病等领域的临床阶段生物药企,维立志博成立以来备受资本青睐,8轮融资募集约10.84亿元,恩然创投、汉康资本、正心谷资本等明星机构纷纷入局,IPO前的最后...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10